Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ-matured type I dendritic cells for immunotherapy.

BACKGROUND AIMS Ex vivo-generated monocyte-derived dendritic cells (DCs) matured with monophosphoryl lipid A (MPLA) and interferon-γ (IFN-γ) can be used as cancer immunotherapy. MPLA/IFN-γ DCs induce Th1 T cell responses and have migratory capacity. Different culture regimens have been used for generation of immunotherapeutic DCs, with varying results. In the present study, culture conditions for MPLA/IFN-γ-matured type I DCs were optimized for clinical application. METHODS DCs were generated from monocytes in the clinical grade culture media CellGro DC, AIM V or X-VIVO 15 in the absence or presence of 2% human serum (HS) and matured with the use of MPLA/IFN-γ. DC yield and DC functionality were assessed. DC functionality was determined by means of analysis of cytokines in culture supernatant, migratory capacity, expression of co-stimulatory molecules, T cell stimulatory capacity of DCs and T helper cell (Th) polarization by the DCs. RESULTS DCs generated in the presence of 2% HS produced low amounts of pro-inflammatory cytokines and could not migrate irrespective of the medium used. In the absence of HS, MPLA/IFN-γ DCs generated in X-VIVO did not migrate either. MPLA/IFN-γ DCs generated in AIM V have slightly lower capacity to induce Th1 cells than do DCs generated in CellGro or X-VIVO. CONCLUSIONS Addition of HS to different GMP culture media is detrimental for pro-inflammatory DC maturation and migration. In the absence of serum, CellGro is the most optimal medium tested for generation of migratory and Th1-inducing MPLA/IFN-γ DCs for cancer immunotherapy.

[1]  M. Baccarani,et al.  Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti‐idiotype vaccination , 2003, British journal of haematology.

[2]  A. ten Brinke,et al.  The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. , 2007, Vaccine.

[3]  K. Yoneda,et al.  Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements. , 2000, Journal of immunological methods.

[4]  L. Frati,et al.  A Comparative Analysis of Serum and Serum-free Media for Generation of Clinical Grade DCs , 2007, Journal of immunotherapy.

[5]  J. Schlom,et al.  Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. , 2012, Blood.

[6]  C. Ries,et al.  In Vitro Generation of Monocyte-Derived Macrophages under Serum-Free Conditions Improves Their Tumor Promoting Functions , 2012, PloS one.

[7]  R. Schumann.  Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. , 2011, Biochemical Society transactions.

[8]  S. Burdach,et al.  Efficacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14+ starting populations. , 2003, Journal of hematotherapy & stem cell research.

[9]  R. Geffers,et al.  Evaluating maturation and genetic modification of human dendritic cells in a new polyolefin cell culture bag system , 2010, Transfusion.

[10]  R. Steinman,et al.  Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. , 1996, Journal of immunological methods.

[11]  E. Read,et al.  Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes , 2009, Transfusion.

[12]  J. Cyster,et al.  Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. , 2005, Annual review of immunology.

[13]  C. Mackay,et al.  The role of chemokine receptors in primary, effector, and memory immune responses. , 2000, Annual review of immunology.

[14]  L. Nielsen,et al.  Generation and Maturation of Dendritic Cells for Clinical Application Under Serum-Free Conditions , 2005, Journal of immunotherapy.

[15]  M. Donia,et al.  Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. , 2013, Vaccine.

[16]  J. Zwaginga,et al.  Monophosphoryl lipid A plus IFNγ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential , 2010, Cancer Immunology, Immunotherapy.

[17]  C. Figdor,et al.  Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells , 2002, Journal of immunotherapy.

[18]  M. Grégoire,et al.  Culture Medium and Protein Supplementation in the Generation and Maturation of Dendritic Cells , 2006, Scandinavian journal of immunology.

[19]  F. Hanisch,et al.  Human Tumor Antigen MUC1 Is Chemotactic for Immature Dendritic Cells and Elicits Maturation but Does Not Promote Th1 Type Immunity 1 , 2005, The Journal of Immunology.

[20]  U. Repnik,et al.  In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. , 2005, Transplant immunology.

[21]  M. Lehner,et al.  Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions. , 2005, Immunology letters.

[22]  Thomas C. Mitchell,et al.  The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.

[23]  D. Schadendorf,et al.  PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. , 2010, Blood.

[24]  M. Hansen,et al.  Differential effects of autologous serum on CD34(+) or monocyte-derived dendritic cells. , 2001, Journal of hematotherapy & stem cell research.

[25]  M. Biffoni,et al.  Recombinant Tumor-Associated MUC1 Glycoprotein Impairs the Differentiation and Function of Dendritic Cells1 , 2005, The Journal of Immunology.

[26]  Simon C Watkins,et al.  The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells1 , 2000, The Journal of Immunology.

[27]  S. Lillevang,et al.  Serum Concentration of the Growth Medium Markedly Affects Monocyte‐Derived Dendritic Cells' Phenotype, Cytokine Production Profile and Capacities to Stimulate in MLR , 2004, Scandinavian journal of immunology.

[28]  J. Kirkwood,et al.  alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.